Liraglutide in combination with acitretin for severe recalcitrant psoriasis

Reid, Carol; Tobin, Anne-Marie; Ahern, Tomás; O’Shea, Donal; Kirby, Brian

doi:10.1111/bjd.12380

Cited by 12 publications

(13 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has, however, been suggested that long-term treatment with liraglutide in a high dose of up to 3 mg daily may be of benefit in patients with refractory psoriasis where immunosuppressive therapy is contraindicated. 11 Also, liraglutide may be considered for treating type 2 diabetes in patients with psoriasis as it seems to have effects even beyond diabetes. Liraglutide treatment leads to bodyweight loss and a decrease in cholesterol levels as confirmed in the present study.…”

Section: Discussionmentioning

confidence: 99%

“…The reported effect of liraglutide on psoriasis from case series and reports seems to be modest and cannot compare to the effect of biological therapy and other available systemic treatments. It has, however, been suggested that long‐term treatment with liraglutide in a high dose of up to 3 mg daily may be of benefit in patients with refractory psoriasis where immunosuppressive therapy is contraindicated . Also, liraglutide may be considered for treating type 2 diabetes in patients with psoriasis as it seems to have effects even beyond diabetes.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Lack of effect of the glucagon‐like peptide‐1 receptor agonist liraglutide on psoriasis in glucose‐tolerant patients – a randomized placebo‐controlled trial

Faurschou

Gyldenløve

Rohde

et al. 2014

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Lack of effect of the glucagon‐like peptide‐1 receptor agonist liraglutide on psoriasis in glucose‐tolerant patients – a randomized placebo‐controlled trial

Faurschou

Gyldenløve

Rohde

et al. 2014

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Several reports demonstrated improvements in psoriasis with GLP-1 agonists [102][103][104][105]. Nevertheless, a randomized controlled trial conducted in patients with psoriasis and obesity showed no statistically significant difference in either the PASI or Dermatology Life Quality Index with liraglutide treatment compared with placebo [106].…”

Section: Hypoglycemic Agentsmentioning

confidence: 98%

Psoriasis and Cardiovascular Risk: A Comprehensive Review

Masson

Lobo²,

Molinero³

2020

Adv Ther

117

129

View full text Add to dashboard Cite

Psoriasis is a systemic inflammatory disorder that involves complex pathogenic interactions between the innate and adaptive immune systems. Individuals with psoriasis have an increased risk of developing other chronic health diseases such cardiovascular disorders. The high incidence of cardiovascular events in the population with psoriasis could be explained by several mechanisms. The high prevalence of traditional cardiovascular risk factors and metabolic abnormalities contributes to the high cardiovascular burden in patients with psoriasis. Likewise, the presence of systemic inflammation in combination with metabolic abnormalities may act in a synergistic manner to increase cardiovascular risk in these patients. This review focused on epidemiologic and clinical evidence linking psoriasis to cardiovascular risk factors and cardiovascular disease. We described the possible pathophysiological mechanisms that justify this association and analyzed the best way to stratify the cardiovascular risk in patients with psoriasis. We also described the usefulness of the therapies frequently used in cardiovascular prevention and analyzed the impact of the specific psoriasis medication on cardiovascular risk factors or major atherosclerotic events. Knowledge of the application of different cardiovascular prevention strategies could mean an advantage in performing the difficult task of estimating cardiovascular risk and treating cardiovascular risk factors in this particular group of patients.

show abstract

“…In one study, acitretin for 4 months was ineffective, but improved PASI and Dermatology Life Quality Index were seen after liraglutide had been initiated [8] . Prospective case series studies demonstrated significant improvements in PASI and epidermal thickness within 7 weeks of GLP-1 receptor agonist treatment in comparison to baseline [9,11] .…”

Section: Clinical Reportsmentioning

confidence: 99%

Glycemic Control in the Treatment of Psoriasis

Ip¹,

Kirchhof

2017

Dermatology

View full text Add to dashboard Cite

Psoriasis is a common chronic inflammatory skin disease that manifests as scaly erythematous plaques as a consequence of keratinocyte hyperproliferation and inflammation. It is commonly associated with diabetes, obesity, and the metabolic syndrome. While there are numerous approved treatment options available, they have limitations including availability, toxicities such as immunosuppression, and high cost. There is increasing evidence to suggest that several hypoglycemic agents used in the treatment of type 2 diabetes, including glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, thiazolidinediones and biguanides, exert beneficial effects in psoriasis. In this review, we summarize the growing evidence supporting the therapeutic role of hypoglycemic agents in psoriasis and discuss the potential underlying mechanisms. We suggest that dermatologists consider the use of hypoglycemic agents in psoriasis especially in cases with coexisting diabetes and in cases in which immunosuppression is contraindicated. Earlier referral to endocrinology in patients with concomitant diabetes may be appropriate.

show abstract

Liraglutide in combination with acitretin for severe recalcitrant psoriasis

Cited by 12 publications

References 8 publications

Lack of effect of the glucagon‐like peptide‐1 receptor agonist liraglutide on psoriasis in glucose‐tolerant patients – a randomized placebo‐controlled trial

Lack of effect of the glucagon‐like peptide‐1 receptor agonist liraglutide on psoriasis in glucose‐tolerant patients – a randomized placebo‐controlled trial

Psoriasis and Cardiovascular Risk: A Comprehensive Review

Glycemic Control in the Treatment of Psoriasis

Contact Info

Product

Resources

About